(Some of the) contents:
A collection of marketing material (2021–2023 so far) concerning the pharmaceutical firm Novo Nordisk's promotion of its GLP1-analogues liraglutide and semaglutide, via promotion of a certain perspective on obesity. The actual advertisements are found here or here (same content, different display modes), also here (a selection). Presentations and two publications collected here, all in Swedish except this one from the Nordic Congress of General Practice in Stavanger 2022.
Complaints about misleading promotion for an ear wax removal screw called "Q-Grips" to the Swedish Consumer Agency, 2020, all in Swedish.
A poster with a suggestion for an internet database of drug advertisements, prepared for the Health Action International (HAI) Annual Meeting November 2008, "There should be an internet database of pharmaceutical advertisements":
Another poster for the HAI meeting above, concerning surrogate variables, "A collection of misleading surrogate end points". Written with members from Healthy Skepticism:
The table from this poster, with the references:
A publication based on the same material, 2013. (doi:10.1001/jamainternmed.2013.3037)
Some material on a hang-over concoction marketed in Sweden, "Revigör", 2007. In Swedish:
revigor_inlagg_GP_070712.pdf
revigor_inlagg_GP_070905.pdf
revigor_replik_julin_GP_070731.pdf